1
|
Oi I, Ito I, Tanabe N, Konishi S, Ibi Y, Hidaka Y, Hamao N, Shirata M, Nishioka K, Imai S, Yasutomo Y, Kadowaki S, Hirai T. Investigation of predictors for in-hospital death or long-term hospitalization in community-acquired pneumonia with risk factors for aspiration. Eur Clin Respir J 2024; 11:2335721. [PMID: 38586609 PMCID: PMC10997353 DOI: 10.1080/20018525.2024.2335721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Accepted: 03/22/2024] [Indexed: 04/09/2024] Open
Abstract
Background It is known that the mortality of pneumonia in patients with risk factors for aspiration is worse than that in those without these risk factors. However, it is still unknown which risk factors for aspiration predict prognosis. Therefore, we aimed to determine which risk factors for aspiration are associated with death or prolonged hospitalization. Methods We prospectively followed patients with community-acquired pneumonia at a single hospital providing acute to chronic care in Japan until they died or were discharged. Patients at any risk of aspiration were included. The associations between pneumonia severity, individual risk factors for aspiration, and in-hospital death or prolonged hospitalization were investigated. Overall survival was estimated by the Kaplan - Meier method, and the factors associated with in-hospital death or prolonged hospitalization were investigated by multivariate analysis using factors selected by a stepwise method. Results In total, 765 patients with pneumonia and risk factors for aspiration were recruited. One hundred and ten patients deceased, and 259 patients were hospitalized over 27 days. In-hospital death increased as the number of risk factors for aspiration increased. In the multivariate analysis, male, impaired consciousness, acidemia, elevated blood urea nitrogen, and bedridden status before the onset of pneumonia were associated with in-hospital death (odds ratio [OR]: 2.5, 2.5, 3.6, 3.1, and 2.6; 95% confidence interval [CI]: 1.6-4.1, 1.4-4.2, 1.6-8.0, 1.9-5.0, and 1.6-4.2 respectively). In the Cox regression analysis, these factors were also associated with in-hospital death. None of the vital signs at admission were associated. Tachycardia, elevated blood urea nitrogen, hyponatremia, and bedridden status were associated with hospitalization for >27 days (OR: 4.1, 2.3, 4.3, and 2.9; 95% CI: 1.3-12.9, 1.5-3.4, 2.0-9.4, and 2.0-4.0, respectively). Conclusions Blood sampling findings and bedridden status are useful for predicting in-hospital mortality and long-term hospitalization in patients with pneumonia and any risk factor for aspiration.
Collapse
Affiliation(s)
- Issei Oi
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
| | - Isao Ito
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
- Department of Internal Medicine, Ono Municipal Hospital, Ono, Hyogo, Japan
| | - Naoya Tanabe
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
- Department of Internal Medicine, Ono Municipal Hospital, Ono, Hyogo, Japan
| | - Satoshi Konishi
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
- Department of Internal Medicine, Ono Municipal Hospital, Ono, Hyogo, Japan
| | - Yumiko Ibi
- Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
| | - Yu Hidaka
- Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
| | - Nobuyoshi Hamao
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
| | - Masahiro Shirata
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
| | - Kensuke Nishioka
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
| | - Seiichiro Imai
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
| | - Yoshiro Yasutomo
- Department of Internal Medicine, Ono Municipal Hospital, Ono, Hyogo, Japan
| | - Seizo Kadowaki
- Department of Internal Medicine, Ono Municipal Hospital, Ono, Hyogo, Japan
| | - Toyohiro Hirai
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
| |
Collapse
|
2
|
Matsumoto M, Ito I, Kadowaki S. Drug-induced interstitial lung disease due to over-the-counter cold medicine taken daily for 25 years: a case report. J Med Case Rep 2023; 17:83. [PMID: 36849989 PMCID: PMC9969705 DOI: 10.1186/s13256-022-03717-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2022] [Accepted: 12/08/2022] [Indexed: 03/01/2023] Open
Abstract
INTRODUCTION We report a rare case of drug-induced interstitial lung disease due to over-the-counter cold medicine taken daily for 25 years to clear the patient's head. CASE PRESENTATION A 77-year-old Japanese man presented to our hospital with a worsening cough that started 5 years ago. Chest radiographs and computed tomography images showed bilateral opacities, and transbronchial lung biopsy specimens showed an organizing pneumonia pattern. He reported taking the same over-the-counter cold medicine daily for the past 25 years to clear his head. We suspected that the cold medicine caused the lung opacities and asked him to stop taking them. His cough, general fatigue, and chest infiltrate gradually diminished. However, 6 months later, he resumed the same treatment because of a cold. The following month, he presented with severe worsening cough and chest radiographical findings. We diagnosed drug-induced interstitial lung disease. He improved by stopping the cold medicine again and taking prednisolone. CONCLUSIONS Over-the-counter cold medicines are easily accessible at the drugstore. In cases of diffuse lung disease, we should consider drug-induced interstitial lung disease due to over-the-counter cold medicine, which patients have been taking not only for weeks or months but also years.
Collapse
Affiliation(s)
- Masataka Matsumoto
- Department of Respiratory Medicine, Kitaharima Medical Center, 926-250 Ichiba-Cho, Ono, Hyogo, 675-1392, Japan.
| | - Isao Ito
- grid.411217.00000 0004 0531 2775Department of Respiratory Medicine, Kyoto University Hospital, 54 Shogoin-Kawaharacho, Sakyo, Kyoto, 606-8507 Japan ,Department of Internal Medicine, Ono Municipal Hospital, 323 Naka-Cho, Ono, Hyogo 675-1332 Japan
| | - Seizo Kadowaki
- Department of Internal Medicine, Ono Municipal Hospital, 323 Naka-Cho, Ono, Hyogo 675-1332 Japan
| |
Collapse
|
3
|
Oi I, Ito I, Tanabe N, Konishi S, Hamao N, Shirata M, Imai S, Yasutomo Y, Kadowaki S, Matsumoto H, Hidaka Y, Morita S, Hirai T. Protein C activity as a potential prognostic factor for nursing home-acquired pneumonia. PLoS One 2022; 17:e0274685. [PMID: 36223389 PMCID: PMC9555634 DOI: 10.1371/journal.pone.0274685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Accepted: 09/02/2022] [Indexed: 11/07/2022] Open
Abstract
Introduction Despite the poor prognosis for nursing home acquired pneumonia (NHAP), a useful prognostic factor is lacking. We evaluated protein C (PC) activity as a predictor of in-hospital death in patients with NHAP and community-acquired pneumonia (CAP). Methods This prospective, observational study included all patients hospitalized with pneumonia between July 2007 and December 2012 in a single hospital. We measured PC activity at admission and investigated whether it was different between survivors and non-survivors. We also examined whether PC activity < 55% was a predictor for in-hospital death of pneumonia by logistic regression analysis with CURB-65 items (confusion, blood urea >20 mg/dL, respiratory rate >30/min, and blood pressure <90/60 mmHg, age >65). When it was a useful prognostic factor for pneumonia, we combined PC activity with the existing prognostic scores, the pneumonia severity index (PSI) and CURB-65, and analyzed its additional effect by comparing the areas under the receiver operating characteristic curves (AUCs) of the modified and original scores. Results Participants comprised 75 NHAP and 315 CAP patients. PC activity was lower among non-survivors than among survivors in NHAP and all-pneumonia (CAP+NHAP). PC activity <55% was a useful prognostic predictor for NHAP (Odds ratio 7.39 (95% CI; 1.59–34.38), and when PSI or CURB-65 was combined with PC activity, the AUC improved (from 0.712 to 0.820 for PSI, and 0.657 to 0.734 for CURB-65). Conclusions PC activity was useful for predicting in-hospital death of pneumonia, especially in NHAP, and became more useful when combined with the PSI or CURB-65.
Collapse
Affiliation(s)
- Issei Oi
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
| | - Isao Ito
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
- Department of Internal Medicine, Ono Municipal Hospital, Ono, Hyogo, Japan
- * E-mail:
| | - Naoya Tanabe
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
- Department of Internal Medicine, Ono Municipal Hospital, Ono, Hyogo, Japan
| | - Satoshi Konishi
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
- Department of Internal Medicine, Ono Municipal Hospital, Ono, Hyogo, Japan
| | - Nobuyoshi Hamao
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
| | - Masahiro Shirata
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
| | - Seiichiro Imai
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
| | - Yoshiro Yasutomo
- Department of Internal Medicine, Ono Municipal Hospital, Ono, Hyogo, Japan
| | - Seizo Kadowaki
- Department of Internal Medicine, Ono Municipal Hospital, Ono, Hyogo, Japan
| | - Hisako Matsumoto
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
| | - Yu Hidaka
- Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University
| | - Satoshi Morita
- Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University
| | - Toyohiro Hirai
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan
| |
Collapse
|
4
|
Bando H, Kumagai S, Kotani D, Saori M, Habu T, Tsushima T, Hara H, Kadowaki S, Kato K, Chin K, Yamaguchi K, Kageyama SI, Hojo H, Nakamura M, Tachibana H, Wakabayashi M, Fukutani M, Fuse N, Nishikawa H, Kojima T. 1211P A multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (EPOC1802). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Doi T, Patel M, Falchook G, Koyama T, Friedman C, Piha-Paul S, Gutierrez M, Abdul-Karim R, Awad M, Adkins D, Takahashi S, Kadowaki S, Cheng B, Ikeda N, Laadem A, Yoshizuka N, Qian M, Dosunmu O, Arkenau HT, Johnson M. 453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
6
|
Bai LY, Chiu CF, Kadowaki S, Robert M, Hara H, Hong M, Bergamo F, Pernot S, Cunningham D, Lin CY, Keam B, Matsumura Y, Enya K, Waxman I, Jin L, Ngo D, Drews U, Mancao C, Le Berre MA, Kato K. 1209P A phase II study of regorafenib in combination with nivolumab in patients with recurrent or metastatic solid tumors: Results of the ESCC cohort. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
7
|
Saori M, Nakamura Y, Sawada K, Horasawa S, Kadowaki S, Kato K, Ueno M, Oki E, Satoh T, Komatsu Y, Tukachinsky H, Lee J, Madison R, Sokol E, Pavlick D, Aiyer A, Fabrizio D, Venstrom J, Oxnard G, Yoshino T. 80P Blood tumor mutational burden (bTMB) and efficacy of immune checkpoint inhibitors (ICIs) in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
8
|
Sawada K, Yamashita R, Horasawa S, Fujisawa T, Yoshikawa A, Nakamura Y, Taniguchi H, Kadowaki S, Hosokawa M, Kodama T, Kato K, Satoh T, Komatsu Y, Shiota M, Yasui H, Yamazaki K, Yoshino T. 60MO Gut microbiota and efficacy of immune-checkpoint inhibitors (ICIs) in patients (pts) with advanced solid tumor: SCRUM-Japan MONSTAR-SCREEN. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.340] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
9
|
Ogata T, Narita Y, Kumanishi R, Nakazawa T, Matsubara Y, Kodama H, Nakata A, Honda K, Masuishi T, Bando H, Kadowaki S, Ando M, Ito S, Tajika M, Muro K. 1418P Chronological improvement in the survival of advanced gastric cancer patients in the past 15 years. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
10
|
Shiraishi K, Masuishi T, Ogata T, Sugiyama K, Nishikawa N, Shibata K, Kudo C, Takayanagi N, Narita Y, Uda H, Kadowaki S, Ando M, Kitagawa C, Kataoka M, Muro K. P-155 A phase I study of FLOT as first-line therapy for Japanese patients with advanced gastric cancer including patients with or without severe peritoneal metastasis. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
11
|
Kumagai K, Yagi S, Yamaguchi T, Nagashima K, Nomura T, Watanabe M, Makuuchi R, Kawakami K, Otsuka S, Matsushima T, Kadowaki S, Haruta S, Cho H, Yamada T, Kakihara N, Imai Y, Fukunaga H, Saeki Y, Kanaji S, Boku N, Goto M. P-83 The efficacy of chemotherapy for gastric cancer with early recurrence during or after adjuvant S-1. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Kato K, Masuishi T, Fushiki K, Nakano S, Kawamoto Y, Narita Y, Tsushima T, Harada K, Kadowaki S, Todaka A, Yuki S, Tajika M, Machida N, Komatsu Y, Yasui H, Muro K, Kawakami T. Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer. ESMO Open 2021; 6:100179. [PMID: 34119801 PMCID: PMC8209093 DOI: 10.1016/j.esmoop.2021.100179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 05/12/2021] [Accepted: 05/16/2021] [Indexed: 11/28/2022] Open
Abstract
Background Nivolumab (NIVO) and irinotecan (IRI) are standard treatments for refractory advanced gastric cancer (AGC); however, it is unclear which drug should be administered first or in which cases. The tumor growth rate (TGR) during preceding treatment is reported to be associated with tumor response in metastatic colorectal cancer patients treated with regorafenib or trifluridine/tipiracil, suggesting that TGR may be useful for drug selection. Therefore, we evaluated the association between TGR during preceding treatment and the tumor response to NIVO or IRI. Patients and methods We retrospectively evaluated consecutive AGC patients treated with NIVO or IRI and divided them into slow-growing (Slow) and rapid-growing (Rapid) groups according to TGR and the presence or absence of new lesions (NL+/NL−, respectively) during preceding treatment (Slow group: NL− with low TGR <0.30%/day; Rapid group: NL+ or high TGR ≥0.30%/day). Results A total of 117 patients (Rapid/Slow groups, 72/45; NIVO/IRI groups, 32/85) were eligible. All baseline characteristics except peritoneal metastases were similar between patients treated with NIVO and IRI in the Rapid and Slow groups. The response rate was significantly higher in patients treated with NIVO compared with IRI [31%/3%; odds ratio (OR), 13.8; P = 0.01; adjusted OR, 52; P = 0.002] in the Slow group, but there was no difference between patients treated with NIVO and IRI (5%/8%; OR, 0.68; P = 0.73; adjusted OR, 0.94; P = 0.96) in the Rapid group. Disease control rate, progression-free survival, and overall survival were consistent with these results. Conclusions Our findings suggest that NIVO treatment is a more favorable option for patients with slow-growing tumors, and NIVO and IRI are similarly recommended for patients with rapid-growing tumors in refractory AGC. TGR and NL emergence during preceding treatment may be helpful for drug selection and warrant further investigation. NIVO and IRI are standard treatments for refractory AGC, although it is unclear which should be administered first. TGR may be useful for drug selection, therefore we evaluated the association between TGR and the tumor response to NIVO or IRI. In the Slow group, the response rate (RR) was significantly higher in patients treated with NIVO compared with IRI. In the Rapid group, there was no significant difference in RR between the NIVO and IRI groups. TGR and NL emergence during preceding treatment may be useful for drug selection.
Collapse
Affiliation(s)
- K Kato
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - T Masuishi
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
| | - K Fushiki
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| | - S Nakano
- Cancer Center, Hokkaido University Hospital, Sapporo, Japan
| | - Y Kawamoto
- Cancer Center, Hokkaido University Hospital, Sapporo, Japan
| | - Y Narita
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - T Tsushima
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| | - K Harada
- Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan
| | - S Kadowaki
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - A Todaka
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| | - S Yuki
- Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan
| | - M Tajika
- Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan
| | - N Machida
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| | - Y Komatsu
- Cancer Center, Hokkaido University Hospital, Sapporo, Japan
| | - H Yasui
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| | - K Muro
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - T Kawakami
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
| |
Collapse
|
13
|
Shirata M, Ito I, Tanabe N, Konishi S, Oi I, Hamao N, Matsumoto H, Yasutomo Y, Kadowaki S, Hirai T. Risk factors associated with methicillin-resistant Staphylococcus aureus isolation from serially collected sputum samples of patients hospitalized with pneumonia. J Infect Chemother 2021; 27:1323-1328. [PMID: 34016538 DOI: 10.1016/j.jiac.2021.04.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 03/27/2021] [Accepted: 04/30/2021] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Risk factors associated with the new detection of methicillin-resistant Staphylococcus aureus (MRSA) during hospitalization remain unclear. This study aimed to identify risk factors associated with MRSA isolation from the sputum of patients admitted with pneumonia, during their hospitalization. METHODS Patients were prospectively enrolled from 2003 to 2012. Sputum samples were collected for bacterial cultures on days 1, 4, 7, 11, and 14 of hospitalization and thereafter. Cases of MRSA first isolated from sputum obtained before day 4 were defined as "carriage on admission." Cases of MRSA first isolated on day 4 and thereafter, were defined as "new detection after admission." Statistical analysis was used to investigate the risk factors associated with MRSA isolation. RESULTS MRSA was isolated from 167 of 1,008 patients (carriage: 47; new detection: 120). Multivariate analysis revealed that the risk factors for MRSA carriage were activities of daily living (ADL) disability prior to admission (odds ratio [OR], 2.92; 95% confidence interval [CI], 1.37-6.22) and hospitalization within the previous 90 days (OR, 3.75; 95% CI, 1.90-7.41). ADL disability prior to admission (risk ratio [RR], 1.82; 95% CI, 1.17-2.84) and a high pneumonia severity index score upon admission (RR, 2.20; 95% CI, 1.37-3.65) were risk factors for new detection of MRSA. CONCLUSIONS Several risk factors were found to be associated with MRSA carriage and/or its new detection, based on the sputum samples from patients admitted with pneumonia. These factors may be indicators for selective surveillance and the early implementation of infection control measures.
Collapse
Affiliation(s)
- Masahiro Shirata
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo, Kyoto, 606-8507, Japan
| | - Isao Ito
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo, Kyoto, 606-8507, Japan; Department of Internal Medicine, Ono Municipal Hospital, 323 Naka-cho, Ono, Hyogo, 675-1332, Japan.
| | - Naoya Tanabe
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo, Kyoto, 606-8507, Japan; Department of Internal Medicine, Ono Municipal Hospital, 323 Naka-cho, Ono, Hyogo, 675-1332, Japan
| | - Satoshi Konishi
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo, Kyoto, 606-8507, Japan; Department of Internal Medicine, Ono Municipal Hospital, 323 Naka-cho, Ono, Hyogo, 675-1332, Japan
| | - Issei Oi
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo, Kyoto, 606-8507, Japan
| | - Nobuyoshi Hamao
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo, Kyoto, 606-8507, Japan
| | - Hisako Matsumoto
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo, Kyoto, 606-8507, Japan
| | - Yoshiro Yasutomo
- Department of Internal Medicine, Ono Municipal Hospital, 323 Naka-cho, Ono, Hyogo, 675-1332, Japan
| | - Seizo Kadowaki
- Department of Internal Medicine, Ono Municipal Hospital, 323 Naka-cho, Ono, Hyogo, 675-1332, Japan
| | - Toyohiro Hirai
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo, Kyoto, 606-8507, Japan
| |
Collapse
|
14
|
Takashima A, Chin K, Minashi K, Kadowaki S, Nishina T, Izawa N, Amagai K, Machida N, Goto M, Taku K, Ishizuka N, Takahari D. 158P A phase II study of trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX study): Final report. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
15
|
Hamao N, Ito I, Konishi S, Tanabe N, Shirata M, Oi I, Tsukino M, Matsumoto H, Yasutomo Y, Kadowaki S, Hirai T. Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial. BMC Pulm Med 2020; 20:160. [PMID: 32503515 PMCID: PMC7275365 DOI: 10.1186/s12890-020-01198-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2020] [Accepted: 05/22/2020] [Indexed: 02/08/2023] Open
Abstract
Background Ceftriaxone (CTRX) and ampicillin/sulbactam (ABPC/SBT) are recommended by various guidelines as the first-line antibiotics for community-acquired pneumonia (CAP). However, which of these antibiotics is more effective for treating non-aspiration CAP remains unclear. Methods This study was a prospective, single-center, open-label, quasi-randomized controlled trial. Patients with adult CAP without risk for aspiration were allocated to either a CTRX or ABPC/SBT group based on the date of hospital admission. Macrolide was added to patients in each group. The primary outcome was the clinical response in the validated per-protocol (VPP) population at end of treatment (EOT). The secondary outcomes were clinical response during treatment and at end of study (EOS) in the VPP population, and mortality rate at day 30 in the modified intention-to-treat (MITT) population. Results Of 696 screened patients, 433 patients were excluded and 263 patients were allocated to receive either of the treatments. Males comprised 54% of patients and mean age and PSI were 62.1 ± 19.8 years and 69.3 ± 30.0, respectively, with 124 patients allocated to the CTRX group and 138 patients allocated to the ABPC/SBT group. The clinical effectiveness rate for the VPP population at EOT was 90% in the CTRX and 96% in the ABPC/SBT group (p = 0.072, 95% confidence interval [CI] of risk difference [RD]: − 12.6–0.8%). No significant difference in effectiveness at day 4 was observed between the CTRX and ABPC/SBT groups (p = 0.079, 95%CI of RD: − 12.1–0.4%), but at day 7, ABPC/SBT was significantly more effective than CTRX in the VPP population (p = 0.047, 95%CI of RD: − 13.3–-0.4%). No significant difference in late response at EOS was seen between CTRX and ABPC/SBT groups: cure (89 [86%] and 102 [94%]), relapse (5 [5%] and 1 [1%]) and failure (10 [10%] and 5 [5%]; p = 0.053). Deaths within 30 days in MITT population was higher in CTRX group (4 [3%]) than in ABPC/SBT group (0 [0%]) (p = 0.048, 95%CI of RD: 0.1–6.3%). Conclusion No significant difference in effectiveness was found between ABPC/SBT and CTRX at EOT. However, ABPC/SBT might be more effective in the early phase of treatment. Trial registration UMIN-CTR, UMIN000037464. Registered 25 July 2019 – Retrospectively registered, https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042262
Collapse
Affiliation(s)
- Nobuyoshi Hamao
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaracho, Sakyo, Kyoto, 606-8507, Japan
| | - Isao Ito
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaracho, Sakyo, Kyoto, 606-8507, Japan. .,Department of Internal Medicine, Ono Municipal Hospital, 323 Naka-cho, Ono, Hyogo, 675-1332, Japan.
| | - Satoshi Konishi
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaracho, Sakyo, Kyoto, 606-8507, Japan.,Department of Internal Medicine, Ono Municipal Hospital, 323 Naka-cho, Ono, Hyogo, 675-1332, Japan
| | - Naoya Tanabe
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaracho, Sakyo, Kyoto, 606-8507, Japan.,Department of Internal Medicine, Ono Municipal Hospital, 323 Naka-cho, Ono, Hyogo, 675-1332, Japan
| | - Masahiro Shirata
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaracho, Sakyo, Kyoto, 606-8507, Japan
| | - Issei Oi
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaracho, Sakyo, Kyoto, 606-8507, Japan
| | - Mitsuhiro Tsukino
- Department of Internal Medicine, Ono Municipal Hospital, 323 Naka-cho, Ono, Hyogo, 675-1332, Japan.,Department of Respiratory Medicine, Hikone Municipal Hospital, 1882 Hassakacho, Hikone, Shiga, 522-8539, Japan
| | - Hisako Matsumoto
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaracho, Sakyo, Kyoto, 606-8507, Japan
| | - Yoshiro Yasutomo
- Department of Internal Medicine, Ono Municipal Hospital, 323 Naka-cho, Ono, Hyogo, 675-1332, Japan
| | - Seizo Kadowaki
- Department of Internal Medicine, Ono Municipal Hospital, 323 Naka-cho, Ono, Hyogo, 675-1332, Japan
| | - Toyohiro Hirai
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-kawaracho, Sakyo, Kyoto, 606-8507, Japan
| |
Collapse
|
16
|
Oi I, Ito I, Tanabe N, Konishi S, Hamao N, Yasutomo Y, Kadowaki S, Hirai T. Cefepime vs. meropenem for moderate-to-severe pneumonia in patients at risk for aspiration: An open-label, randomized study. J Infect Chemother 2020; 26:181-187. [DOI: 10.1016/j.jiac.2019.08.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2019] [Revised: 07/16/2019] [Accepted: 08/07/2019] [Indexed: 10/26/2022]
|
17
|
Masuishi T, Taniguchi H, Sugiyama K, Kato K, Mitani S, Honda K, Narita Y, Kadowaki S, Ura T, Ando M, Muro K. Eribulin in BRAF V600E-mutant metastatic colorectal cancer: case series and potential rationale. Ann Oncol 2019; 29:1330-1331. [PMID: 29635451 DOI: 10.1093/annonc/mdy107] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- T Masuishi
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - H Taniguchi
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
| | - K Sugiyama
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - K Kato
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - S Mitani
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - K Honda
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Y Narita
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - S Kadowaki
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - T Ura
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - M Ando
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - K Muro
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| |
Collapse
|
18
|
Cho B, Kato K, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y. Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): The phase III ATTRACTION-3 study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.028] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Kadowaki S, Yamazaki S, Kotani Y, Tsuji T, Sakoda N, Kobayashi Y, Horio N, Goto T, Muraoka G, Ozawa S, Suezawa T, Kuroko Y, Tateishi A, Shimizu S, Kasahara S. P1833The c-fos mRNA expression reveals persistent myocardial stretch in the right ventricle during asphyxiated cardiac arrest. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Donation after circulatory death (DCD) heart transplantation has been debated over the past decades because of the shortage of donor. The right ventricular dysfunction is one of the remaining problems for clinical implication of DCD heart transplantation. DCD hearts suffering from the volume overload have a potential to aggravate the right ventricular dysfunction after heart transplantation. The c-fos mRNA is one of the “immediate” response genes to mechanical stresses, such as myocardial cell stretch, without neural and humoral factors. In this study, we assessed myocardial stretch during asphyxiated cardiac arrest using c-fos mRNA expression.
Purpose
The purpose of this study is to reveal the impact of right ventricular volume overload during asphyxiated cardiac arrest.
Methods
Male Wistar rats (8 weeks of age, n=18) were anesthetized with paralyzed ventilation. The trachea was dissected and ligated to initiate asphyxiation. Hearts were harvested at 3 time points: 0, 15 and 30 minutes after termination of the ventilation. Free walls of right and left ventricle were sectioned and immersed in RNA stabilization solution as soon as possible. Total RNA was extracted from these tissues using a guanidine thiocyanate-phenol-chloroform method and cDNA was synthesized using a reverse transcriptase. Next, we measured the quantified expression level by using the droplet digital PCR method with a probe and primers for c-fos gene. Expression of c-fos level was divided by extracted TATA binding protein (TBP) level as a control marker, the ratio of c-fos and TBP was used in analysis.
Results
In the left ventricle, the expression of c-fos rapidly increased by 15 minutes (0.81±0.24 (c-fos/TBP), p<0.05 by one-way ANOVA followed by the Dunnett's test) compared to at 0 minutes (0.21±0.06), but the expression level recovered to the baseline level at 30 minutes after termination of the ventilation (0.19±0.03). On the other hand, in the right ventricle, the c-fos expression was gradually elevated and peaked at 30 minutes (0.88±0.20, p<0.05 by the Dunnett's test) compared to at 0 minutes (0.22±0.05).
Conclusion
These results suggest that the volume overload to the right ventricle during asphyxiated cardiac arrest prolongs compared to that to the left ventricle, which may cause the right ventricular dysfunction after DCD heart transplantation.
Collapse
Affiliation(s)
| | - S Yamazaki
- National Cerebral and Cardiovascular Center, Osaka, Japan
| | - Y Kotani
- Okayama University, Okayama, Japan
| | - T Tsuji
- Okayama University, Okayama, Japan
| | - N Sakoda
- Okayama University, Okayama, Japan
| | | | - N Horio
- Okayama University, Okayama, Japan
| | - T Goto
- Okayama University, Okayama, Japan
| | | | - S Ozawa
- Okayama University, Okayama, Japan
| | | | - Y Kuroko
- Okayama University, Okayama, Japan
| | | | - S Shimizu
- National Cerebral and Cardiovascular Center, Osaka, Japan
| | | |
Collapse
|
20
|
Kang Y, Chin K, Chung H, Kadowaki S, Oh S, Nakayama N, Lee K, Hara H, Chung I, Tsuda M, Park S, Hosaka H, Hironaka S, Miyata Y, Ryu M, Takeuchi M, Baba H, Hyodo I, Bang Y, Boku N. A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz183.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Kadowaki S, Izawa N, Minashi K, Nishina T, Yamanaka T, Muro K, Sunakawa Y, Hironaka S, Kajiwara T, Kawakami Y, Nakajima T. Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz157] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Kato K, Kojima T, Saeki H, Hara H, Kajiwara T, Hironaka S, Nakatsumi H, Kadowaki S, Kagawa Y, Esaki T, Moriwaki T, Kobayashi T, Izawa N, Nomura S, Kuwata T, Fujii S, Okamoto W, Shitara K, Ohtsu A, Yoshino T. The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced esophageal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Masuishi T, Kadowaki S, Hirano H, Kawai S, Yamada T, Moriwaki T, Machida N, Boku N, Muro K. Impact of adding ramucirumab to paclitaxel in patients with advanced gastric cancer according to the level of ascites: A multicenter retrospective study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
24
|
Kadowaki S, Ishigami H, Muro K, Yoshida S, Hirono Y, Tomita T, Yabusaki H, Kusumoto T, Ota M, Kodera Y, Tsuji Y, Hidemura A, Hachiya O, Oba K, Kitayama J. An exploratory study of intraperitoneal paclitaxel combined with mFOLFOX6 for peritoneal disseminated gastric cancer patients with inadequate oral intake. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Pham T, Fujiyoshi A, Hisamatsu T, Kadota A, Kadowaki S, Zaid M, Kunimura A, Tori S, Horie M, Miura M, Ueshima H. P2508Smoking associates with higher incidence and progression of coronary atherosclerosis in a community-based sample of japanese men: a cohort study. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- T Pham
- Shiga University of Medical Science, Otsu, Japan
| | - A Fujiyoshi
- Shiga University of Medical Science, Otsu, Japan
| | | | - A Kadota
- Shiga University of Medical Science, Otsu, Japan
| | - S Kadowaki
- Shiga University of Medical Science, Otsu, Japan
| | - M Zaid
- Shiga University of Medical Science, Otsu, Japan
| | - A Kunimura
- Shiga University of Medical Science, Otsu, Japan
| | - S Tori
- Shiga University of Medical Science, Otsu, Japan
| | - M Horie
- Shiga University of Medical Science, Otsu, Japan
| | - M Miura
- Shiga University of Medical Science, Otsu, Japan
| | - H Ueshima
- Shiga University of Medical Science, Otsu, Japan
| | | |
Collapse
|
26
|
Kadota A, Miura K, Fujiyoshi A, Hisamatsu T, Kadowaki S, Zaid M, Miyagawa N, Kondo K, Kunimura A, Okamura T, Ueshima H. P4448The association of coronary artery calcification progression, albuminuria and estimated glomerular filtration rate among general population. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- A Kadota
- Shiga University of Medical Science, Center for Epidemiologic Research in Asia, Otsu, Japan
| | - K Miura
- Shiga University of Medical Science, Center for Epidemiologic Research in Asia, Otsu, Japan
| | - A Fujiyoshi
- Shiga University of Medical Science, Department of Public Health, Otsu, Japan
| | - T Hisamatsu
- Shimane University, Dpeartment of Enviromental Medicine and Public Health, Izumo, Japan
| | - S Kadowaki
- Shiga University of Medical Science, Department of Public Health, Otsu, Japan
| | - M Zaid
- Shiga University of Medical Science, Center for Epidemiologic Research in Asia, Otsu, Japan
| | - N Miyagawa
- Shiga University of Medical Science, Department of Public Health, Otsu, Japan
| | - K Kondo
- Shiga University of Medical Science, Department of Public Health, Otsu, Japan
| | - A Kunimura
- Shiga University of Medical Science, Center for Epidemiologic Research in Asia, Otsu, Japan
| | - T Okamura
- Keio University School of Medicine, Department of Preventive Medicine and Public Health, Tokyo, Japan
| | - H Ueshima
- Shiga University of Medical Science, Center for Epidemiologic Research in Asia, Otsu, Japan
| | | |
Collapse
|
27
|
Hasegawa H, Ando M, Yatabe Y, Mitani S, Honda K, Masuishi T, Narita Y, Taniguchi H, Kadowaki S, Ura T, Muro K. Site-specific Chemotherapy Based on Predicted Primary Site by Pathological Profile for Carcinoma of Unknown Primary Site. Clin Oncol (R Coll Radiol) 2018; 30:667-673. [PMID: 30196846 DOI: 10.1016/j.clon.2018.06.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2018] [Revised: 05/14/2018] [Accepted: 06/06/2018] [Indexed: 01/20/2023]
Abstract
AIMS Although platinum-based combination chemotherapies are commonly used for unfavourable subsets of cancer of unknown primary (CUP), the prognosis remains poor. Several studies have suggested that gene expression profiling or immunohistochemistry was useful for the prediction of primary sites in CUP, and site-specific therapy based on predicted primary sites might improve overall outcomes. In Japan, to identify primary sites, immunohistochemical tests were commonly used for CUP in clinical practice. However, it is unclear whether site-specific therapy based on predicted primary sites by pathological examination contributes survival benefit for unfavourable CUP subsets. PATIENTS AND METHODS In this study, 122 patients with unfavourable subsets of CUP were retrospectively reviewed. Ninety patients assigned to cohort A after July 2012 had received chemotherapy according to predicted primary sites; 32 patients assigned to cohort B before June 2012 had received platinum-based empiric chemotherapy. RESULTS In cohort A, 56 patients (62.2%) with predicted primary sites by pathological examination received site-specific therapy; 34 patients (37.8%) with unpredictable primary sites received platinum-based empiric chemotherapy, the same as cohort B. The median overall survival was 20.3 months in patients with predictable primary sites in cohort A and 10.7 months in those of cohort B, with a significant difference between these cohorts (P = 0.03, adjusted hazard ratio = 0.57, 95% confidence interval 0.34-0.94). CONCLUSION Site-specific therapy based on predicted primary sites by pathological examination could improve prognosis in patients with an unfavourable subset of CUP.
Collapse
Affiliation(s)
- H Hasegawa
- Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan; Department of Gastroenterology and Hepatology, Osaka National Hospital, Osaka, Japan
| | - M Ando
- Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan.
| | - Y Yatabe
- Pathology and Molecular Diagnosis, Aichi Cancer Center, Nagoya, Japan
| | - S Mitani
- Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan
| | - K Honda
- Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan
| | - T Masuishi
- Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan
| | - Y Narita
- Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan
| | - H Taniguchi
- Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan
| | - S Kadowaki
- Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan
| | - T Ura
- Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan
| | - K Muro
- Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan
| |
Collapse
|
28
|
Mitani S, Oze I, Kadowaki S, Masuishi T, Narita Y, Taniguchi H, Ura T, Ando M, Tajika M, Makita C, Kodaira T, Uemura N, Abe T, Muro K. Risk of second malignancies after definitive therapy for esophageal cancer: A competing risk analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Narita Y, Sasaki E, Yatabe Y, Kato K, Okano H, Mitani S, Honda K, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Ando M, Tajika M, Ito S, Muro K. PD-L1 immunohistochemistry (IHC) by three different assays and molecular profiling in tissue microarray (TMA) of gastric cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.060] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Mitani S, Taniguchi H, Honda K, Masuishi T, Narita Y, Kadowaki S, Ura T, Ando M, Tajika M, Muro K. Analysis of efficacy and prognostic factors in second-line chemotherapy for BRAF V600E mutant metastatic colorectal cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.058] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Yamashita A, Murakami T, Kadowaki S, Yoshida K, Ito E, Matsuda N, Chang F, Hattori N, Miyai I, Ugawa Y. Spike-timing dependent plasticity at spinal motoneurons. Brain Stimul 2017. [DOI: 10.1016/j.brs.2017.01.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
32
|
Taniguchi H, Narita Y, Kadowaki S, Ura T, Ando M, Muro K, Hamauchi S, Tsushima T, Yokota T, Todaka A, Machida N, Fukutomi A, Onozawa Y, Yasui H, Mori K, Yamazaki K. 218TiP A phase Ib study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplation (MODURATE). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw581.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Taniguchi H, Narita Y, Kadowaki S, Ura T, Ando M, Muro K, Hamauchi S, Tsushima T, Yokota T, Todaka A, Machida N, Fukutomi A, Onozawa Y, Yasui H, Mori K, Yamazaki K. 218TiP A phase Ib study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplation (MODURATE). Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00375-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
34
|
Fujiwara Y, Ishigami H, Fukushima R, Nashimoto A, Yabusaki H, Imamoto H, Imano M, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Kitayama J. Phase III study comparing intraperitoneal paclitaxel plus S-1/paclitaxel with S-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Mitani S, Kadowaki S, Oze I, Masuishi T, Narita Y, Taniguchi H, Ura T, Ando M, Tajika M, Makita C, Kodaira T, Uemura N, Abe T, Muro K. Chemoradiotherapy versus surgery for clinical stage I esophageal squamous cell carcinoma: A long-term comparison. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.63] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Ebisutani C, Ito I, Kitaichi M, Tanabe N, Mishima M, Kadowaki S. A case of non-specific interstitial pneumonia with recurrent gastric carcinoma and anti-Jo-1 antibody positive myositis. Respir Investig 2016; 54:289-93. [PMID: 27424830 DOI: 10.1016/j.resinv.2016.02.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Revised: 02/02/2016] [Accepted: 02/16/2016] [Indexed: 12/01/2022]
Abstract
We report the first case of non-specific interstitial pneumonia (NSIP) in a patient with cancer-associated myositis (CAM) that emerged along with the recurrence of the cancer. A 60-year-old woman, with a history of partial gastrectomy for gastric cancer 11 years ago, presented with exertional dyspnea with anti-Jo-1 antibody-positive myositis. Surgical lung biopsy showed NSIP with metastatic gastric cancer. Accordingly, her condition was diagnosed as CAM with cancer recurrence. In patients with a history of cancer, development of myositis may indicate cancer recurrence; therefore, careful observation would be necessary.
Collapse
Affiliation(s)
- Chikara Ebisutani
- Department of Internal Medicine, Ono Municipal Hospital, 323 Nakacho, Ono City, Hyogo 675-1332, Japan; Department of Gastrointestinal Medicine, Kobe Minimally Invasive Treatment Center of Cancer (KMCC), 8-5-1, Minatojima-nakamachi, Chuo-ku, Kobe City 650-0046, Japan.
| | - Isao Ito
- Department of Respiratory Medicine, Kyoto University Hospital, 54 Shogoin-kawaracho, Sakyo, Kyoto 606-8507, Japan.
| | - Masanori Kitaichi
- Department of Pathology, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180, Nagasone-cho, Kita-ku, Sakai, Osaka 591-8555, Japan.
| | - Naoya Tanabe
- Department of Respiratory Medicine, Kyoto University Hospital, 54 Shogoin-kawaracho, Sakyo, Kyoto 606-8507, Japan.
| | - Michiaki Mishima
- Department of Respiratory Medicine, Kyoto University Hospital, 54 Shogoin-kawaracho, Sakyo, Kyoto 606-8507, Japan.
| | - Seizo Kadowaki
- Department of Internal Medicine, Ono Municipal Hospital, 323 Nakacho, Ono City, Hyogo 675-1332, Japan.
| |
Collapse
|
37
|
Komori A, Taniguchi H, Kito Y, Hamauchi S, Masuishi T, Hasegawa H, Mitani S, Narita Y, Kadowaki S, Ura T, Ando M, Mori K, Yasui H, Muro K, Yamazaki K. 169P Serum CA19-9 response is an early predictive marker for the efficacy of regorafenib in refractory metastatic colorectal cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Narita Y, Kadowaki S, Oze I, Taniguchi H, Ura T, Ando M, Ito S, Yatabe Y, Tajika M, Muro K. 205P Development of nomograms including HER2 status for predicting survival in metastatic gastric cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv523.66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Taniguchi H, Hasegawa H, Masuishi T, Narita Y, Komori A, Kadowaki S, Ura T, Muro K. P-232 Characterization of serum HER2 ECD level in patients with metastatic colorectal cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Nomura M, Abe T, Kodaira T, Oze I, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Takahari D, Ura T, Andoh M, Kawai R, Uemura N, Tomita N, Tachibana H, Tanaka T, Tajika M, Niwa Y, Muro K. Comparison of Surgery with Definitive Chemoradiotherapy for Potentially Resectable Esophageal Cancer: a Propensity-Score Analysis. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Shinozaki E, Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Machida N, Yuki S, Ooki A, Kajiura S, Kimura T, Yamanaka T, Sasaki T, Shitara K, Nagatsuma A, Yoshino T, Ochiai A, Ohtsu A. Prognostic Impact of Her2, Egfr, and C-Met Status on Overall Survival of Advanced Gastric Cancer Patients Treated with Standard Chemotherapy Without Trastuzumab in a First-Line Treatment: a Japanese Multicenter Collaborative Retrospective Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Kadowaki S, Enomoto H, Moriya A, Murakami T, Nakamura K, Naktani-Enomoto S, Mochizuki H, Kobayashi S, Ugawa Y. P1064: Phasic muscle contraction influence upon the quadripulse stimulation (QPS) after effects. Clin Neurophysiol 2014. [DOI: 10.1016/s1388-2457(14)51093-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Nitta S, Ando M, Yamaguchi K, Kondo C, Taniguchi H, Kadowaki S, Takahari D, Ura T, Muro K. Cancer of Unknown Primary Site: Review of Consecutive Cases in Aichi Cancer Center Hospital. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
44
|
Komori A, Kondo C, Yamaguchi K, Taniguchi H, Kadowaki S, Takahari D, Ura T, Ando M, Muro K. Feasibility of Oxaliplatin Containing Regimens for Advanced Gastric Cancer (AGC) with Peritoneal Metastases. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Narumi T, Watanabe T, Arimoto T, Kadowaki S, Otaki Y, Honda Y, Hasegawa H, Honda S, Kubota I. Obesity paradox is not recognized in chronic heart failure patients with metabolic syndrome. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p1508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Kadowaki S, Watanabe T, Narumi T, Otaki Y, Honda Y, Honda S, Hasegawa M, Shishido T, Kubota I. Combination of heart-type fatty acid binding protein and QRS prolongation can risk-stratify patients with chronic heart failure. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p1481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Bando H, Yoshino T, Yuki S, Shinozaki E, Nishina T, Kadowaki S, Yamazaki K, Kajiura S, Tsuchihara K, Fujii S, Yamanaka T, Ohtsu A. Clinical Outcome of Japanese Metastatic Colorectal Cancer Patients Harbouring the KRAS p.G13D Mutation Treated with Cetuximab + Irinotecan. Jpn J Clin Oncol 2012; 42:1146-51. [DOI: 10.1093/jjco/hys160] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Ooki A, Yamashita K, Yamaguchi K, Asayama M, Kadowaki S, Hara H, Yamada-murano T, Arima M, Tada M, Watanabe M. Functional Analysis of Reprimo as a Suppressor Gene in Gastric Cancer. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32381-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
49
|
Yamazaki K, Bando H, Shinozaki E, Nishina T, Kadowaki S, Yuki S, Kajiura S, Tsuchihara K, Fujii S, Yamanaka T, Yoshino T. Clinical Outcome of Cetuximab for Metastatic Colorectal Cancer Patients Harboring KRAS Codon61, KRAS Codon146, BRAF, NRAS or PIK3CA Mutations. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32332-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
50
|
Shinozaki E, Bando H, Nishina T, Yamazaki K, Kadowaki S, Yuki S, Kajiura S, Tsuchihara K, Fujii S, Yoshino T. Clinical Outcome of Cetuximab for Metastatic Colorectal Cancer Patients Harboring Kras CODON61, Kras CODON146, Braf, Nras or PIK3CA Mutations. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33185-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|